Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation

Alberto Morales Salinas, Antonio Coca, Michael H. Olsen, Ramiro A. Sanchez, Weimar K. Sebba-Barroso, Richard Kones, Vicente Bertomeu-Martinez, Javier Sobrino, Luis Alcocer, Daniel J. Pineiro, Fernando Lanas, Carlos A. Machado, Fernando Aguirre-Palacios, Jose Ortellado, Gonzalo Perez, Rodrigo Sabio, Orlando Landrove, Delfin Rodriguez-Leyva, Alfredo Duenas-Herrera, Ayelen Rodriguez PortellesJose Z. Parra-Carrillo, Daniel L. Piskorz, Alfonso Bryce-Moncloa, Gabriel Waisman, Yuichiro Yano, Hector Ventura, Marcelo Orias, Dorairaj Prabhakaran, J. Sundström, Jiguang Wang, Louise M. Burrell, Alta E. Schutte, Patricio Lopez-Jaramillo, Eduardo Barbosa, Josep Redon, Michael A. Weber, Carl J. Lavie, Agustin Ramirez, Pedro Ordunez, Salim Yusuf, Alberto Zanchetti

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Hypertension is a leading risk factor for disease burden globally. An unresolved question is whether grade 1 hypertension (140-159/90-99 mm Hg) with low (cardiovascular mortality <1% at 10 years) to moderate (cardiovascular mortality ≥1% and <5% at 10 years) absolute total cardiovascular risk (CVR) should be treated with antihypertensive agents. A virtual international consultation process was undertaken to summarize the opinions of select experts. After holistic analysis of all epidemiological, clinical, psychosocial, and public health elements, this consultation process reached the following consensus in hypertensive adults aged <80 years: (1) The question of whether drug treatment in grade 1 should be preceded by a period of some weeks or months during which only lifestyle measures are recommended cannot be evidence based, but the consensus opinion is to have a period of lifestyle alone reserved only to patients with grade 1 “isolated” hypertension (grade 1 uncomplicated hypertension with low absolute total CVR, and without other major CVR factors and risk modifiers). (2) The initiation of antihypertensive drug therapy in grade 1 hypertension with moderate absolute total CVR should not be delayed. (3) Men ≥55 years and women ≥60 years with uncomplicated grade 1 hypertension should automatically be classified within the moderate absolute total CVR category, even in the absence of other major CVR factors and risk modifiers. (4) Statins should be considered along with blood-pressure lowering therapy, irrespective of cholesterol levels, in patients with grade 1 hypertensive with moderate CVR.

Original languageEnglish
Pages (from-to)198-225
Number of pages28
JournalCurrent Problems in Cardiology
Volume42
Issue number7
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Antihypertensive Agents
Referral and Consultation
Hypertension
Therapeutics
Life Style
Consensus
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mortality
Expert Testimony
Public Health
Cholesterol
Blood Pressure
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk : An International Expert Consultation. / Morales Salinas, Alberto; Coca, Antonio; Olsen, Michael H.; Sanchez, Ramiro A.; Sebba-Barroso, Weimar K.; Kones, Richard; Bertomeu-Martinez, Vicente; Sobrino, Javier; Alcocer, Luis; Pineiro, Daniel J.; Lanas, Fernando; Machado, Carlos A.; Aguirre-Palacios, Fernando; Ortellado, Jose; Perez, Gonzalo; Sabio, Rodrigo; Landrove, Orlando; Rodriguez-Leyva, Delfin; Duenas-Herrera, Alfredo; Rodriguez Portelles, Ayelen; Parra-Carrillo, Jose Z.; Piskorz, Daniel L.; Bryce-Moncloa, Alfonso; Waisman, Gabriel; Yano, Yuichiro; Ventura, Hector; Orias, Marcelo; Prabhakaran, Dorairaj; Sundström, J.; Wang, Jiguang; Burrell, Louise M.; Schutte, Alta E.; Lopez-Jaramillo, Patricio; Barbosa, Eduardo; Redon, Josep; Weber, Michael A.; Lavie, Carl J.; Ramirez, Agustin; Ordunez, Pedro; Yusuf, Salim; Zanchetti, Alberto.

In: Current Problems in Cardiology, Vol. 42, No. 7, 01.07.2017, p. 198-225.

Research output: Contribution to journalReview article

Morales Salinas, A, Coca, A, Olsen, MH, Sanchez, RA, Sebba-Barroso, WK, Kones, R, Bertomeu-Martinez, V, Sobrino, J, Alcocer, L, Pineiro, DJ, Lanas, F, Machado, CA, Aguirre-Palacios, F, Ortellado, J, Perez, G, Sabio, R, Landrove, O, Rodriguez-Leyva, D, Duenas-Herrera, A, Rodriguez Portelles, A, Parra-Carrillo, JZ, Piskorz, DL, Bryce-Moncloa, A, Waisman, G, Yano, Y, Ventura, H, Orias, M, Prabhakaran, D, Sundström, J, Wang, J, Burrell, LM, Schutte, AE, Lopez-Jaramillo, P, Barbosa, E, Redon, J, Weber, MA, Lavie, CJ, Ramirez, A, Ordunez, P, Yusuf, S & Zanchetti, A 2017, 'Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation', Current Problems in Cardiology, vol. 42, no. 7, pp. 198-225. https://doi.org/10.1016/j.cpcardiol.2017.03.001
Morales Salinas, Alberto ; Coca, Antonio ; Olsen, Michael H. ; Sanchez, Ramiro A. ; Sebba-Barroso, Weimar K. ; Kones, Richard ; Bertomeu-Martinez, Vicente ; Sobrino, Javier ; Alcocer, Luis ; Pineiro, Daniel J. ; Lanas, Fernando ; Machado, Carlos A. ; Aguirre-Palacios, Fernando ; Ortellado, Jose ; Perez, Gonzalo ; Sabio, Rodrigo ; Landrove, Orlando ; Rodriguez-Leyva, Delfin ; Duenas-Herrera, Alfredo ; Rodriguez Portelles, Ayelen ; Parra-Carrillo, Jose Z. ; Piskorz, Daniel L. ; Bryce-Moncloa, Alfonso ; Waisman, Gabriel ; Yano, Yuichiro ; Ventura, Hector ; Orias, Marcelo ; Prabhakaran, Dorairaj ; Sundström, J. ; Wang, Jiguang ; Burrell, Louise M. ; Schutte, Alta E. ; Lopez-Jaramillo, Patricio ; Barbosa, Eduardo ; Redon, Josep ; Weber, Michael A. ; Lavie, Carl J. ; Ramirez, Agustin ; Ordunez, Pedro ; Yusuf, Salim ; Zanchetti, Alberto. / Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk : An International Expert Consultation. In: Current Problems in Cardiology. 2017 ; Vol. 42, No. 7. pp. 198-225.
@article{daf0952cd8934528b4dc92992e9b524b,
title = "Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation",
abstract = "Hypertension is a leading risk factor for disease burden globally. An unresolved question is whether grade 1 hypertension (140-159/90-99 mm Hg) with low (cardiovascular mortality <1{\%} at 10 years) to moderate (cardiovascular mortality ≥1{\%} and <5{\%} at 10 years) absolute total cardiovascular risk (CVR) should be treated with antihypertensive agents. A virtual international consultation process was undertaken to summarize the opinions of select experts. After holistic analysis of all epidemiological, clinical, psychosocial, and public health elements, this consultation process reached the following consensus in hypertensive adults aged <80 years: (1) The question of whether drug treatment in grade 1 should be preceded by a period of some weeks or months during which only lifestyle measures are recommended cannot be evidence based, but the consensus opinion is to have a period of lifestyle alone reserved only to patients with grade 1 “isolated” hypertension (grade 1 uncomplicated hypertension with low absolute total CVR, and without other major CVR factors and risk modifiers). (2) The initiation of antihypertensive drug therapy in grade 1 hypertension with moderate absolute total CVR should not be delayed. (3) Men ≥55 years and women ≥60 years with uncomplicated grade 1 hypertension should automatically be classified within the moderate absolute total CVR category, even in the absence of other major CVR factors and risk modifiers. (4) Statins should be considered along with blood-pressure lowering therapy, irrespective of cholesterol levels, in patients with grade 1 hypertensive with moderate CVR.",
author = "{Morales Salinas}, Alberto and Antonio Coca and Olsen, {Michael H.} and Sanchez, {Ramiro A.} and Sebba-Barroso, {Weimar K.} and Richard Kones and Vicente Bertomeu-Martinez and Javier Sobrino and Luis Alcocer and Pineiro, {Daniel J.} and Fernando Lanas and Machado, {Carlos A.} and Fernando Aguirre-Palacios and Jose Ortellado and Gonzalo Perez and Rodrigo Sabio and Orlando Landrove and Delfin Rodriguez-Leyva and Alfredo Duenas-Herrera and {Rodriguez Portelles}, Ayelen and Parra-Carrillo, {Jose Z.} and Piskorz, {Daniel L.} and Alfonso Bryce-Moncloa and Gabriel Waisman and Yuichiro Yano and Hector Ventura and Marcelo Orias and Dorairaj Prabhakaran and J. Sundstr{\"o}m and Jiguang Wang and Burrell, {Louise M.} and Schutte, {Alta E.} and Patricio Lopez-Jaramillo and Eduardo Barbosa and Josep Redon and Weber, {Michael A.} and Lavie, {Carl J.} and Agustin Ramirez and Pedro Ordunez and Salim Yusuf and Alberto Zanchetti",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.cpcardiol.2017.03.001",
language = "English",
volume = "42",
pages = "198--225",
journal = "Current Problems in Cardiology",
issn = "0146-2806",
publisher = "Mosby Inc.",
number = "7",

}

TY - JOUR

T1 - Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk

T2 - An International Expert Consultation

AU - Morales Salinas, Alberto

AU - Coca, Antonio

AU - Olsen, Michael H.

AU - Sanchez, Ramiro A.

AU - Sebba-Barroso, Weimar K.

AU - Kones, Richard

AU - Bertomeu-Martinez, Vicente

AU - Sobrino, Javier

AU - Alcocer, Luis

AU - Pineiro, Daniel J.

AU - Lanas, Fernando

AU - Machado, Carlos A.

AU - Aguirre-Palacios, Fernando

AU - Ortellado, Jose

AU - Perez, Gonzalo

AU - Sabio, Rodrigo

AU - Landrove, Orlando

AU - Rodriguez-Leyva, Delfin

AU - Duenas-Herrera, Alfredo

AU - Rodriguez Portelles, Ayelen

AU - Parra-Carrillo, Jose Z.

AU - Piskorz, Daniel L.

AU - Bryce-Moncloa, Alfonso

AU - Waisman, Gabriel

AU - Yano, Yuichiro

AU - Ventura, Hector

AU - Orias, Marcelo

AU - Prabhakaran, Dorairaj

AU - Sundström, J.

AU - Wang, Jiguang

AU - Burrell, Louise M.

AU - Schutte, Alta E.

AU - Lopez-Jaramillo, Patricio

AU - Barbosa, Eduardo

AU - Redon, Josep

AU - Weber, Michael A.

AU - Lavie, Carl J.

AU - Ramirez, Agustin

AU - Ordunez, Pedro

AU - Yusuf, Salim

AU - Zanchetti, Alberto

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Hypertension is a leading risk factor for disease burden globally. An unresolved question is whether grade 1 hypertension (140-159/90-99 mm Hg) with low (cardiovascular mortality <1% at 10 years) to moderate (cardiovascular mortality ≥1% and <5% at 10 years) absolute total cardiovascular risk (CVR) should be treated with antihypertensive agents. A virtual international consultation process was undertaken to summarize the opinions of select experts. After holistic analysis of all epidemiological, clinical, psychosocial, and public health elements, this consultation process reached the following consensus in hypertensive adults aged <80 years: (1) The question of whether drug treatment in grade 1 should be preceded by a period of some weeks or months during which only lifestyle measures are recommended cannot be evidence based, but the consensus opinion is to have a period of lifestyle alone reserved only to patients with grade 1 “isolated” hypertension (grade 1 uncomplicated hypertension with low absolute total CVR, and without other major CVR factors and risk modifiers). (2) The initiation of antihypertensive drug therapy in grade 1 hypertension with moderate absolute total CVR should not be delayed. (3) Men ≥55 years and women ≥60 years with uncomplicated grade 1 hypertension should automatically be classified within the moderate absolute total CVR category, even in the absence of other major CVR factors and risk modifiers. (4) Statins should be considered along with blood-pressure lowering therapy, irrespective of cholesterol levels, in patients with grade 1 hypertensive with moderate CVR.

AB - Hypertension is a leading risk factor for disease burden globally. An unresolved question is whether grade 1 hypertension (140-159/90-99 mm Hg) with low (cardiovascular mortality <1% at 10 years) to moderate (cardiovascular mortality ≥1% and <5% at 10 years) absolute total cardiovascular risk (CVR) should be treated with antihypertensive agents. A virtual international consultation process was undertaken to summarize the opinions of select experts. After holistic analysis of all epidemiological, clinical, psychosocial, and public health elements, this consultation process reached the following consensus in hypertensive adults aged <80 years: (1) The question of whether drug treatment in grade 1 should be preceded by a period of some weeks or months during which only lifestyle measures are recommended cannot be evidence based, but the consensus opinion is to have a period of lifestyle alone reserved only to patients with grade 1 “isolated” hypertension (grade 1 uncomplicated hypertension with low absolute total CVR, and without other major CVR factors and risk modifiers). (2) The initiation of antihypertensive drug therapy in grade 1 hypertension with moderate absolute total CVR should not be delayed. (3) Men ≥55 years and women ≥60 years with uncomplicated grade 1 hypertension should automatically be classified within the moderate absolute total CVR category, even in the absence of other major CVR factors and risk modifiers. (4) Statins should be considered along with blood-pressure lowering therapy, irrespective of cholesterol levels, in patients with grade 1 hypertensive with moderate CVR.

UR - http://www.scopus.com/inward/record.url?scp=85017370272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017370272&partnerID=8YFLogxK

U2 - 10.1016/j.cpcardiol.2017.03.001

DO - 10.1016/j.cpcardiol.2017.03.001

M3 - Review article

AN - SCOPUS:85017370272

VL - 42

SP - 198

EP - 225

JO - Current Problems in Cardiology

JF - Current Problems in Cardiology

SN - 0146-2806

IS - 7

ER -